Rosetta Genomics (Rosetta Genomics) EV-to-EBIT : 0.00 (As of May. 25, 2024)

Rosetta Genomics EV-to-EBIT Chart

Rosetta Genomics Annual Data
	Trend	Dec07	Dec08	Dec09	Dec10	Dec11	Dec12	Dec13	Dec14	Dec15	Dec16
EV-to-EBIT		Get a 7-Day Free Trial					-1.37	-1.05	-2.58	-0.74	-0.43

Rosetta Genomics Quarterly Data
	Dec10	Mar11	Jun11	Dec11	Jun12	Dec12	Jun13	Dec13	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Jun17
EV-to-EBIT	Get a 7-Day Free Trial															-0.62	-0.90	-0.67	-0.43	-0.71

Competitive Comparison of Rosetta Genomics's EV-to-EBIT

For the Diagnostics & Research subindustry, Rosetta Genomics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Rosetta Genomics's EV-to-EBIT Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Rosetta Genomics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Rosetta Genomics's EV-to-EBIT falls into.

Rosetta Genomics EV-to-EBIT Calculation

Rosetta Genomics's EV-to-EBIT for today is calculated as:

Rosetta Genomics's current Enterprise Value is $0.00 Mil.
Rosetta Genomics's EBIT for the trailing twelve months (TTM) ended in Jun. 2017 adds up the quarterly data reported by the company within the most recent 12 months, which was $-10.20 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rosetta Genomics  (OTCPK:ROSGQ) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Rosetta Genomics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2017 is calculated as:

Rosetta Genomics's Enterprise Value for the quarter that ended in Jun. 2017 was $7.21 Mil.
Rosetta Genomics's EBIT for the trailing twelve months (TTM) ended in Jun. 2017 adds up the quarterly data reported by the company within the most recent 12 months, which was $-10.20 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rosetta Genomics EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Rosetta Genomics's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Rosetta Genomics (Rosetta Genomics) Business Description